Yesterday morning, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announced the success of its second Lennox-Gastaut Syndrome Phase III trial, evaluating pipeline drug Epidiolex, the …
It is a day full of great news for the biotech-verse as Array Biopharma Inc (NASDAQ:ARRY) shares are shooting 54% today on back …
What does the future hold for GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)? Morgan Stanley analyst Andrew Berens weighs in on the cannabinoid maker, providing investors …
A recent article by Reuters indicates that GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has made the strategic decision to hire an investment bank as …
Piper Jaffray analyst Joshua Schimmer provides a 2H16 outlook on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH). Exiting second-quarter earnings season, GWPH remains one of …
Piper Jaffray analyst Joshua Schimmer was out today with some commentary on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), following the news that the Drug Enforcement Administration (DEA) will …
In a research report issued Thursday, Merrill Lynch analyst Tazeen Ahmad reiterated a Buy rating on shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with …
Juno Therapeutics Inc (NASDAQ:JUNO) is up 20% in early trading after the FDA removed the clinical hold on its Phase 2 clinical trial of …
The aftershocks from Brexit continue to weigh on the markets, with the iShares Nasdaq Biotech ETF (IBB) down more than 3% Monday. Among the equities in …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares are up 11.5%, after the drug maker announced positive results from its phase 3 trial of Epidiolex in …
